Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments

Aliment Pharmacol Ther. 2018 Sep;48(6):664-670. doi: 10.1111/apt.14914. Epub 2018 Jul 25.

Abstract

Background: The incidence of hepatocellular carcinoma (HCC) in patients with a history of curatively-treated HCC is higher than in patients with no history of HCC even after sustained virologic response (SVR).

Aim: To investigate differences in the patterns of HCC development after SVR in patients with a history of curatively-treated HCC and those with no history of HCC, based on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) findings.

Methods: EOB-MRI was performed in 164 patients with HCV cirrhosis who achieved SVR by interferon-free direct-acting antiviral (DAA) therapy just before the start of therapy. Changes in EOB-MRI findings after SVR were compared prospectively between patients with (n = 62) and without (n = 102) a history of HCC.

Results: The incidence of HCC after SVR was higher in patients with a history of HCC (P < 0.0001). The prevalence of nonhypervascular hypointense nodules (NHHNs) by EOB-MRI was significantly higher in patients with a history of HCC at baseline (P = 0.05). Although there was no difference in the incidence of the hypervascularisation of baseline NHHNs to typical hypervascular HCC between patients with and without a history of HCC, the incidence of direct emergence of hypervascular HCC despite the absence of NHHNs at baseline was significantly higher in patients with a history of HCC (P < 0.0001).

Conclusion: Direct emergence of hypervascular HCC and a higher prevalence of NHHNs before DD therapy contributed to the higher incidence of HCC after SVR. (UMIN000017020).

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Antiviral Agents / therapeutic use*
  • Carcinoma, Hepatocellular / epidemiology*
  • Carcinoma, Hepatocellular / pathology*
  • Carcinoma, Hepatocellular / therapy
  • Carcinoma, Hepatocellular / virology
  • Female
  • Gadolinium DTPA
  • Hepatitis C / complications
  • Hepatitis C / diagnosis
  • Hepatitis C / drug therapy*
  • Hepatitis C / epidemiology
  • Humans
  • Incidence
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / drug therapy
  • Liver Cirrhosis / epidemiology
  • Liver Cirrhosis / virology
  • Liver Neoplasms / epidemiology*
  • Liver Neoplasms / pathology*
  • Liver Neoplasms / therapy
  • Liver Neoplasms / virology
  • Magnetic Resonance Imaging / methods
  • Male
  • Neoplasm Recurrence, Local / epidemiology*
  • Neoplasm Recurrence, Local / virology
  • Remission Induction
  • Risk Factors
  • Sustained Virologic Response

Substances

  • Antiviral Agents
  • gadolinium ethoxybenzyl DTPA
  • Gadolinium DTPA

Associated data

  • UMIN-CTR/UMIN000017020